YTHDC2 and neoplasm: The correlation between the expression levels of YTHDC2 and prognosis has been mixed: Lower expression levels were associated with poorer prognosis in lung and endocrine malignancies [79,80], higher expression levels were associated with a poorer prognosis and higher tumor stage in prostate and breast cancer [79,81], and confounding results were seen in gastric cancer [79,82].